Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -122.76% is 113% below its 5-year average of -57.68%, near the low end of its 5-year range (-122.76%–-18.40%).
As of the fiscal period ended Tuesday, June 30, 2026. 19.00% below its 12-month average of -103.16%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -122.76%.
RETURN ON EQUITY (ROE)
-122.76%
RETURN ON EQUITY (ROE) AVG TTM
-103.16%
RETURN ON EQUITY (ROE) AVG 3Y
-74.73%
RETURN ON EQUITY (ROE) AVG 5Y
-57.68%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-19.00%
CURRENT VS 3Y AVG
-64.28%
CURRENT VS 5Y AVG
-112.81%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-192.21%
vs the sector median at left
Pulmonx Corporation
Market Cap
$75.18M
Return on Equity (ROE)
-122.76%
TTM Avg
-103.16%
3Y Avg
-74.73%
5Y Avg
-57.68%
Market Cap
$75.95M
Return on Equity (ROE)
-51.09%
TTM Avg
-35.88%
3Y Avg
-53.46%
5Y Avg
-40.30%
Market Cap
$77.54M
Return on Equity (ROE)
N/A
TTM Avg
354.96%
3Y Avg
354.96%
5Y Avg
354.96%
Market Cap
$73.27M
Return on Equity (ROE)
-94.81%
TTM Avg
-84.90%
3Y Avg
-70.34%
5Y Avg
-58.48%
Market Cap
$76.74M
Return on Equity (ROE)
-77.12%
TTM Avg
-270.75%
3Y Avg
-187.09%
5Y Avg
-136.77%
Market Cap
$78.29M
Return on Equity (ROE)
-55.97%
TTM Avg
-55.58%
3Y Avg
-51.87%
5Y Avg
-151.31%
Market Cap
$78.07M
Return on Equity (ROE)
-1542.57%
TTM Avg
-254.55%
3Y Avg
-187.52%
5Y Avg
-143.69%
Market Cap
$72.83M
Return on Equity (ROE)
-250.39%
TTM Avg
-122.53%
3Y Avg
-92.00%
5Y Avg
-67.18%
Market Cap
$78.59M
Return on Equity (ROE)
-6.05%
TTM Avg
-96.60%
3Y Avg
16.82%
5Y Avg
35.21%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pulmonx Corporation (LUNG) | $75.18M | -122.76% | -103.16% | -74.73% | -57.68% |
| SkinHealth Systems Inc. (SKIN)vs › | $75.95M | -51.09% | -35.88% | -53.46% | -40.30% |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $77.54M | N/A | 354.96% | 354.96% | 354.96% |
| Hyperfine, Inc. (HYPR)vs › | $73.27M | -94.81% | -84.90% | -70.34% | -58.48% |
| Outset Medical, Inc. (OM)vs › | $76.74M | -77.12% | -270.75% | -187.09% | -136.77% |
| Sera Prognostics, Inc. (SERA)vs › | $78.29M | -55.97% | -55.58% | -51.87% | -151.31% |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.07M | -1542.57% | -254.55% | -187.52% | -143.69% |
| MindWalk Holdings Corp. (HYFT)vs › | $72.83M | -250.39% | -122.53% | -92.00% | -67.18% |
| vTv Therapeutics Inc. (VTVT)vs › | $78.59M | -6.05% | -96.60% | 16.82% | 35.21% |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $72.32M | -724.01% | 352.19% | 76.05% | 9.78% |
ROE
-122.8%
ROA
-41.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -122.76% |
| 2026-03-31 | -116.28% |
| 2025-12-31 | -99.79% |
| 2025-09-30 | -94.54% |
| 2025-06-30 | -82.41% |
| 2025-03-31 | -73.51% |
| 2024-12-31 | -65.72% |
| 2024-09-30 | -60.80% |
| 2024-06-30 | -57.19% |
| 2024-03-31 | -53.15% |
| 2023-12-31 | -51.42% |
| 2023-09-30 | -48.70% |
| 2023-06-30 | -45.17% |
| 2023-03-31 | -40.96% |
| 2022-12-31 | -38.26% |
| 2022-09-30 | -35.26% |
| 2022-06-30 | -31.16% |
| 2022-03-31 | -28.54% |
| 2021-12-31 | -25.18% |
| 2021-09-30 | -22.16% |
| 2021-06-30 | -18.40% |
| 2021-03-31 | -17.35% |
| 2020-12-31 | -14.25% |
